Qingdao Vland Biotech INC.

SHSE:603739 Stock Report

Market Cap: CN¥3.3b

Qingdao Vland Biotech Past Earnings Performance

Past criteria checks 0/6

Qingdao Vland Biotech's earnings have been declining at an average annual rate of -6.3%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 8.1% per year. Qingdao Vland Biotech's return on equity is 5.2%, and it has net margins of 5.2%.

Key information

-6.3%

Earnings growth rate

-10.1%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate8.1%
Return on equity5.2%
Net Margin5.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Qingdao Vland Biotech's (SHSE:603739) Anemic Earnings Might Be Worse Than You Think

Nov 04
Qingdao Vland Biotech's (SHSE:603739) Anemic Earnings Might Be Worse Than You Think

Investors Shouldn't Be Too Comfortable With Qingdao Vland Biotech's (SHSE:603739) Earnings

May 06
Investors Shouldn't Be Too Comfortable With Qingdao Vland Biotech's (SHSE:603739) Earnings

Recent updates

Why Investors Shouldn't Be Surprised By Qingdao Vland Biotech INC.'s (SHSE:603739) 28% Share Price Surge

Nov 08
Why Investors Shouldn't Be Surprised By Qingdao Vland Biotech INC.'s (SHSE:603739) 28% Share Price Surge

Qingdao Vland Biotech's (SHSE:603739) Anemic Earnings Might Be Worse Than You Think

Nov 04
Qingdao Vland Biotech's (SHSE:603739) Anemic Earnings Might Be Worse Than You Think

Some Qingdao Vland Biotech INC. (SHSE:603739) Shareholders Look For Exit As Shares Take 27% Pounding

Sep 05
Some Qingdao Vland Biotech INC. (SHSE:603739) Shareholders Look For Exit As Shares Take 27% Pounding

Qingdao Vland Biotech INC.'s (SHSE:603739) Popularity With Investors Under Threat As Stock Sinks 26%

Jun 07
Qingdao Vland Biotech INC.'s (SHSE:603739) Popularity With Investors Under Threat As Stock Sinks 26%

Investors Shouldn't Be Too Comfortable With Qingdao Vland Biotech's (SHSE:603739) Earnings

May 06
Investors Shouldn't Be Too Comfortable With Qingdao Vland Biotech's (SHSE:603739) Earnings

Qingdao Vland Biotech INC. (SHSE:603739) Might Not Be As Mispriced As It Looks

Apr 16
Qingdao Vland Biotech INC. (SHSE:603739) Might Not Be As Mispriced As It Looks

Revenue & Expenses Breakdown

How Qingdao Vland Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:603739 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,26566341111
30 Jun 241,26479338114
31 Mar 241,25383340115
31 Dec 231,19981327111
30 Sep 231,21371324111
30 Jun 231,17564321104
31 Mar 231,14062308101
31 Dec 221,16370309102
30 Sep 221,1489230099
30 Jun 221,134109288104
31 Mar 221,141122292103
31 Dec 211,151133291101
30 Sep 211,10013027596
30 Jun 211,07812628191
31 Mar 211,03011627686
31 Dec 2096010926480
30 Sep 2092210328274
30 Jun 208848927875
31 Mar 208708927274
31 Dec 198477826975
30 Sep 198407925378
30 Jun 198248123573
31 Mar 198088422970
31 Dec 188148322770
30 Sep 1880586396121
31 Dec 177998623371
31 Dec 167818324077
31 Dec 157527022783
31 Dec 14728533360

Quality Earnings: 603739 has a large one-off gain of CN¥24.5M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 603739's current net profit margins (5.2%) are lower than last year (5.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 603739's earnings have declined by 6.3% per year over the past 5 years.

Accelerating Growth: 603739's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 603739 had negative earnings growth (-6.7%) over the past year, making it difficult to compare to the Biotechs industry average (1.3%).


Return on Equity

High ROE: 603739's Return on Equity (5.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 14:34
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Qingdao Vland Biotech INC. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiarui LuGuosen Securities Co., Ltd.
Hairong LiuMinsheng Securities Co.
Xuemei YaoZhongtai Securities Co. Ltd.